GO:0060545 positive regulation of necroptotic process: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060545 describes any process that increases the rate, frequency or extent of necroptosis, a programmed necrotic cell death triggered by death domain receptors or Toll-like receptors [1, 3, 4].
• Core positive regulators include RIPK1, RIPK3, MLKL, ZBP1, and TLR3/TLR4 signaling components that assemble the necrosome and execute membrane permeabilization [3, 5, 6].
• Necroptosis amplification is implicated in inflammatory diseases such as cholestatic liver injury, acute kidney injury, airway inflammation, and antitumor immunity [3, 5, 6, 8].
• Negative regulators such as RUBCNL/PACER and autophagy proteins restrain RIPK1 kinase-dependent apoptosis and necroptosis, defining a critical checkpoint.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of positive regulators in disease [1, 4, 8].
• EDITGENE provides end-to-end CRISPR cell model and library screening services to study positive regulation of necroptotic process at scale.
Description
Necroptosis is a form of programmed necrotic cell death that depends on the activation of endogenous signaling pathways downstream of death domain receptors or Toll-like receptors [1, 3]. The Gene Ontology term GO:0060545, positive regulation of necroptotic process, captures any molecular event that increases the rate, frequency, or extent of this death program [3, 4]. Unlike apoptosis, necroptosis leads to plasma membrane rupture and release of damage-associated molecular patterns, making its positive regulation a key node in inflammation and immunity [5, 6]. Understanding which factors amplify necroptosis is therefore central to both basic cell death biology and therapeutic development [3, 8]. Positive regulation of necroptosis is executed by a defined signaling module. Receptor-interacting protein kinase 1 (RIPK1) and RIPK3 form the necrosome, which phosphorylates mixed lineage kinase domain-like pseudokinase (MLKL), driving its oligomerization and membrane translocation [3, 4]. Z-DNA binding protein 1 (ZBP1) acts as a nucleic acid sensor that can directly engage RIPK3 and MLKL to potentiate necroptotic signaling [3, 5, 6]. Toll-like receptor and interferon signaling further lower the threshold for necroptosis activation, illustrating layered positive regulation [5, 8]. For researchers, GO:0060545 provides a structured framework to annotate genes that enhance necroptotic cell death. Experimental evidence from knockout and knock-in models has linked positive regulators to cholestasis-induced liver and kidney injury, house dust mite-induced airway inflammation, sepsis-associated acute kidney injury, and radiation-induced antitumor immunity [3, 5, 6, 8]. This article integrates the QuickGO definition with verified PubMed literature to outline mechanisms, key genes, disease relevance, and CRISPR-based research strategies for studying positive regulation of necroptotic process.
positive regulation of necroptotic process At A Glance
| GO ID | GO:0060545 |
|---|---|
| GO term | positive regulation of necroptotic process |
| Ontology | biological_process |
| Synonym | positive regulation of necroptosis |
| Definition | Any process that increases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. |
| Major function | Amplification of necroptotic signaling through RIPK1-RIPK3-MLKL axis and sensor pathways such as ZBP1 and TLR signaling [3, 4, 6]. |
| Key upstream triggers | Death domain receptors, Toll-like receptors, nucleic acid sensors, and interferon signaling [3, 5, 8]. |
| Representative positive regulators | RIPK1, RIPK3, MLKL, ZBP1, TLR3, TLR4, and downstream inflammatory effectors [3, 5, 6]. |
| Negative regulators | RUBCNL/PACER and autophagy-related proteins that repress RIPK1 kinase-dependent apoptosis and necroptosis. |
| Disease relevance | Cholestatic liver and kidney injury, airway inflammation, sepsis-induced acute kidney injury, and antitumor immunity [3, 5, 6, 8]. |
What Is GO:0060545?
GO:0060545, positive regulation of necroptotic process, is a biological process term defined as any process that increases the rate, frequency or extent of a necroptotic process, a necrotic cell death process that results from the activation of endogenous cellular processes, such as signaling involving death domain receptors or Toll-like receptors. In practical terms, it encompasses molecular events that amplify or accelerate necroptosis execution, including kinase activation, necrosome assembly, and membrane-disrupting effector function [3, 4, 6].
Why Is positive regulation of necroptotic process Important in Cell Biology?
Positive regulation of necroptotic process is important because it determines whether cells commit to a lytic, immunogenic form of death that amplifies inflammation and shapes tissue outcomes [3, 5, 6]. Dysregulated amplification of necroptosis contributes to cholestatic liver and kidney injury, allergic airway inflammation, and sepsis-associated acute kidney injury, while controlled enhancement of necroptosis can potentiate antitumor immunity [3, 5, 6, 8]. Thus, genes annotated to GO:0060545 are candidate therapeutic targets and biomarkers across inflammatory, metabolic, and oncologic diseases [3, 8].
• Defines the molecular events that accelerate necroptosis, a lytic and immunogenic cell death modality [3, 4].
• Central to inflammatory diseases such as cholestasis-induced liver and kidney injury via ZBP1-dependent signaling.
• Contributes to house dust mite-induced airway inflammation through PTRF-IL33-ZBP1 signaling in macrophages.
• Potentiates radiation-induced antitumor immunity via ZBP1-MLKL necroptotic signaling and STING activation.
• Is restrained by negative regulators such as RUBCNL/PACER, highlighting checkpoint control of RIPK1 kinase activity.
• Implicated in sepsis-induced acute kidney injury through EIF2AK2 and AIM2-mediated PANoptosis.
• Provides a framework for annotating genes that enhance necroptotic cell death in pulpitis and other inflammatory conditions.
• Enables CRISPR-based causal testing of positive regulators in disease models [1, 4, 8].
• Supports development of necroptosis-modulating therapeutics for inflammatory and oncologic indications [3, 6].
• Facilitates cross-species and cross-disease comparisons of necroptotic signaling components [3, 5, 6].
What Happens During positive regulation of necroptotic process?
Trigger sensing by death domain receptors and Toll-like receptors
In simple terms: The process starts when danger signals or inflammatory molecules engage receptors on the cell surface.
Positive regulation of necroptosis is initiated when death domain receptors or Toll-like receptors are engaged by their ligands, lowering the threshold for necroptotic signaling [3, 5]. Toll-like receptor and interferon pathways can sensitize cells to necroptosis, and bile acid-induced IRF3 phosphorylation has been shown to mediate cell death and inflammation via ZBP1 regulation. In airway inflammation, PTRF-IL33-ZBP1 signaling in macrophages contributes to necroptosis, demonstrating that receptor-proximal events are critical positive regulatory nodes.
Necrosome assembly and RIPK1-RIPK3 activation
In simple terms: A protein complex called the necrosome forms and turns on the death signal.
Upon trigger sensing, RIPK1 and RIPK3 interact to form the necrosome, a platform that amplifies necroptotic signaling [3, 4]. RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, indicating that necrosome activity is tightly controlled by negative regulators. ZBP1 can directly engage RIPK3 to potentiate necroptotic signaling, bypassing or complementing RIPK1-dependent pathways [3, 5, 6].
MLKL phosphorylation and membrane translocation
In simple terms: The necrosome activates MLKL, which moves to the cell membrane to punch holes.
Activated RIPK3 phosphorylates MLKL, driving its oligomerization and translocation to the plasma membrane, where it executes membrane permeabilization [3, 6]. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation, showing that MLKL-dependent positive regulation can bridge cell death and immune activation. This step is a key amplification point in GO:0060545 because MLKL activation commits the cell to lytic death [3, 6].
Amplification by inflammatory and interferon signaling
In simple terms: Inflammatory signals make the death process stronger and more widespread.
Positive regulation of necroptosis is amplified by inflammatory and interferon signaling. EIF2AK2-targeted activation of AIM2-mediated PANoptosis promotes sepsis-induced acute kidney injury, illustrating crosstalk between necroptotic and other cell death modalities. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via ZBP1 regulation, further demonstrating how inflammatory kinases amplify necroptotic process.
Checkpoint control by autophagy and negative regulators
In simple terms: Brakes exist that keep necroptosis from running out of control.
The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis, defining a checkpoint that opposes positive regulation. Loss of such negative regulators can enhance necroptotic process, and their manipulation is a common experimental strategy to study GO:0060545. Understanding these brakes is essential because unrestrained positive regulation drives pathology in liver, kidney, and airway diseases [3, 5, 8].
Key Genes Involved in GO:0060545 positive regulation of necroptotic process
The following genes and proteins are experimentally implicated in positive regulation of necroptotic process (GO:0060545) based on verified PubMed literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RIPK1 | Kinase that forms necrosome with RIPK3; positive regulator of necroptosis | Target for knockout and kinase-dead point mutation studies |
| RIPK3 | Kinase that phosphorylates MLKL; core necrosome component | Knockout models define requirement for necroptotic process [3, 6] |
| MLKL | Executioner pseudokinase; oligomerizes and permeabilizes membranes | Knock-in and phosphorylation-site mutants test effector function [3, 6] |
| ZBP1 | Nucleic acid sensor that engages RIPK3-MLKL to potentiate necroptosis | Knockout and overexpression models in inflammation and immunity [3, 5, 6] |
| IRF3 | Transcription factor phosphorylated by bile acid signaling; regulates ZBP1 | Point-mutation models test phosphorylation-dependent necroptosis |
| PTRF | Regulates IL33-ZBP1 signaling in macrophages | Knockout models in airway inflammation |
| IL33 | Alarmin that contributes to ZBP1-dependent macrophage necroptosis | Overexpression and knockout in HDM-induced airway inflammation |
| STING | Pathway activated downstream of ZBP1-MLKL in antitumor immunity | Knockout models test immune amplification |
| EIF2AK2 | Kinase targeted to activate AIM2-mediated PANoptosis | Knockout and point-mutation models in sepsis-induced AKI |
| AIM2 | Inflammasome sensor contributing to PANoptosis | Knockout models in sepsis-induced acute kidney injury |
| RUBCNL/PACER | Autophagy protein that represses RIPK1 kinase-dependent apoptosis and necroptosis | Knockout and overexpression models define negative regulation |
| TLR3 | Toll-like receptor that can sensitize cells to necroptosis | Knockout models test receptor-proximal positive regulation |
| TLR4 | Toll-like receptor linked to necroptotic signaling | Knockout models in inflammatory disease [3, 5] |
| CASP8 | Caspase that restrains necroptosis; its loss enhances necroptosis | Knockout models amplify necroptotic process |
| RIPK1 K45A | Kinase-dead mutant used to separate scaffolding from kinase function | Point-mutation knock-in models |
| MLKL S345A | Phosphorylation-site mutant that blocks MLKL activation | Point-mutation knock-in models [3, 6] |
| ZBP1 Zalpha | Domain required for nucleic acid sensing and necroptosis potentiation | Domain-deletion knock-in models [3, 5] |
| STING1 | Adaptor in cytosolic DNA sensing that amplifies antitumor immunity | Knockout models in radiation-induced immunity |
How Is positive regulation of necroptotic process Regulated?
Positive regulation of necroptotic process is controlled at multiple levels. Receptor-proximal signaling through death domain receptors and Toll-like receptors sets the threshold for necrosome formation [3, 5]. RIPK1 kinase activity is a critical checkpoint, and its repression by RUBCNL/PACER and autophagy-related proteins limits necroptosis. Inflammatory kinases such as IRF3 and EIF2AK2 amplify necroptotic signaling through ZBP1 and AIM2-dependent PANoptosis, respectively [3, 8]. Downstream, MLKL phosphorylation and oligomerization are terminal amplification steps that can be modulated by STING pathway activation in antitumor immunity. Together, these layers provide multiple entry points for experimental manipulation of GO:0060545 [3, 4, 6, 8].
positive regulation of necroptotic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ZBP1 | Cholestatic liver and kidney injury; airway inflammation; antitumor immunity | Knockout and knock-in mice; macrophage cell lines [3, 5, 6] |
| IRF3 | Cholestasis-induced liver and kidney injury | Point-mutation knock-in of phosphorylation sites |
| EIF2AK2 | Sepsis-induced acute kidney injury | Knockout and point-mutation models in renal cells |
| AIM2 | Sepsis-induced acute kidney injury | Knockout models in kidney epithelial cells |
| RUBCNL/PACER | Negative regulation of necroptosis; inflammatory disease | Overexpression and knockout cell models |
Cholestatic liver and kidney injury
Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1, directly linking positive regulation of necroptotic process to organ injury. This pathway illustrates how metabolic stress can amplify necroptotic signaling and drive fibrosis.
Airway inflammation and asthma
PTRF-IL33-ZBP1 signaling mediating macrophage necroptosis contributes to house dust mite-induced airway inflammation, implicating GO:0060545 in allergic airway disease. Macrophage necroptosis in this context amplifies inflammatory responses in the lung.
Sepsis-induced acute kidney injury
EIF2AK2 protein targeted activation of AIM2-mediated PANoptosis promotes sepsis-induced acute kidney injury, showing that positive regulation of necroptotic process intersects with PANoptosis in critical illness. This suggests that necroptosis-amplifying kinases are candidate therapeutic targets in sepsis-associated organ failure.
Cancer and antitumor immunity
ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation, demonstrating that positive regulation of necroptosis can be beneficial in oncology. Enhancing necroptosis in tumors may convert immunologically cold tumors into hot tumors.
From positive regulation of necroptotic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is RIPK1 kinase activity required for necroptosis amplification? | RIPK1 K45A point-mutation knock-in cells |
| Does MLKL phosphorylation at S345 drive membrane permeabilization? | MLKL S345A point-mutation knock-in cells [3, 6] |
| Does ZBP1 sensing of nucleic acids potentiate necroptosis? | ZBP1 Zalpha domain deletion knock-in cells [3, 5] |
| Does loss of RUBCNL/PACER enhance necroptotic process? | RUBCNL/PACER knockout cells |
| Can EIF2AK2 activation amplify AIM2-mediated PANoptosis? | EIF2AK2 overexpression and knockout renal cells |
| Does STING pathway activation downstream of MLKL boost antitumor immunity? | STING1 knockout tumor cells and mouse models |
How to Study the positive regulation of necroptotic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on necroptosis | Test requirement of RIPK3, MLKL, ZBP1 [3, 4] |
| Point-mutation knock-in | Specific phosphorylation or kinase-dead effects | MLKL S345A, RIPK1 K45A [3, 4, 6] |
| Overexpression | Gain-of-function sensitization to necroptosis | ZBP1, RIPK3, MLKL overexpression [3, 5, 6] |
| Immunoblotting | Phosphorylation of MLKL and RIPK3 | Pathway activation readout [3, 4] |
| Viability and PI uptake | Cell death quantification | Necroptosis vs apoptosis discrimination [3, 4, 8] |
| RNA-seq | Transcriptional changes during necroptosis | Identify positive regulators and inflammatory programs [3, 5] |
| Library screening | Genome-wide modifiers of necroptosis | Discover novel positive regulators |
| In vivo disease models | Organ injury and immunity phenotypes | Cholestasis, airway inflammation, sepsis-AKI, tumor immunity [3, 5, 6, 8] |
CRISPR knockout and knock-in models
CRISPR knockout of positive regulators such as RIPK3, MLKL, or ZBP1 is used to test requirement for necroptotic process, while knock-in of point mutations (e.g., MLKL S345A) dissects phosphorylation-dependent activation [3, 4, 6]. These models provide causal evidence for GO:0060545 annotations.
Overexpression and reporter assays
Overexpression of ZBP1, RIPK3, or MLKL can sensitize cells to necroptosis and is combined with luciferase or fluorescence reporters to quantify pathway activation [3, 5, 6]. Such assays are useful for screening positive regulators identified by library screening.
Cell death and viability measurements
Necroptosis is quantified using viability assays, propidium iodide uptake, and phosphorylated MLKL immunoblotting, which distinguish necroptosis from apoptosis [3, 4, 8]. These readouts are standard for validating positive regulation of necroptotic process.
In vivo disease models
Mouse models of cholestasis, house dust mite-induced airway inflammation, sepsis-induced acute kidney injury, and radiation-induced antitumor immunity are used to test the impact of necroptosis amplification in vivo [3, 5, 6, 8]. These models link GO:0060545 to human disease phenotypes [3, 8].
How CRISPR Can Be Used to Study GO:0060545 positive regulation of necroptotic process
Knockout
CRISPR knockout of RIPK3, MLKL, ZBP1, or EIF2AK2 is used to determine whether these genes are required for positive regulation of necroptotic process in disease models [3, 4, 8]. Loss-of-function studies in cholestasis, airway inflammation, and sepsis-induced acute kidney injury provide causal evidence for GO:0060545 annotations [3, 5, 8].
Point Mutation
Point-mutation knock-in of RIPK1 K45A or MLKL S345A allows separation of kinase activity from scaffolding function and tests phosphorylation-dependent necroptosis amplification [3, 4, 6]. These models are essential for precise mechanistic dissection of positive regulation.
Knock-in
Knock-in of tagged or domain-deleted alleles (e.g., ZBP1 Zalpha deletion) enables tracking of necrosome components and testing domain-specific contributions to necroptotic process [3, 5]. Such models help map the molecular requirements for GO:0060545.
Overexpression
Overexpression of ZBP1, RIPK3, or MLKL sensitizes cells to necroptosis and is used to identify downstream effectors and inflammatory amplification loops [3, 5, 6]. Overexpression models complement knockout studies by revealing sufficiency of positive regulators.
How EDITGENE Supports positive regulation of necroptotic process Research
Researchers studying positive regulation of necroptotic process-related genes often need to determine whether a candidate gene is causally involved in amplifying necroptotic cell death, and CRISPR-based cell models provide the most direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of necroptotic process research.
Frequently Asked Questions About positive regulation of necroptotic process
What is GO:0060545 positive regulation of necroptotic process?
GO:0060545 is a Gene Ontology biological process term defined as any process that increases the rate, frequency or extent of a necroptotic process, a necrotic cell death process resulting from activation of endogenous cellular processes such as death domain receptor or Toll-like receptor signaling [3, 4].
What genes are involved in positive regulation of necroptotic process?
Key genes include RIPK1, RIPK3, MLKL, ZBP1, IRF3, PTRF, IL33, STING1, EIF2AK2, AIM2, and RUBCNL/PACER, based on verified literature [3, 4, 5, 6, 8].
How is necroptosis positively regulated?
Positive regulation occurs through receptor-proximal sensing, necrosome assembly, MLKL phosphorylation and membrane translocation, and amplification by inflammatory and interferon signaling [3, 4, 6, 8].
What diseases are linked to positive regulation of necroptosis?
Cholestatic liver and kidney injury, house dust mite-induced airway inflammation, sepsis-induced acute kidney injury, and antitumor immunity are linked to this process [3, 5, 6, 8].
What is the role of ZBP1 in necroptosis?
ZBP1 is a nucleic acid sensor that engages RIPK3-MLKL signaling to potentiate necroptosis in inflammation and antitumor immunity [3, 5, 6].
How do researchers study positive regulation of necroptotic process?
Researchers use CRISPR knockout, point-mutation knock-in, overexpression, viability assays, immunoblotting, RNA-seq, and in vivo disease models [3, 4, 5, 6, 8].
What is the difference between necroptosis and apoptosis?
Necroptosis is a lytic, RIPK1-RIPK3-MLKL-dependent death program, whereas apoptosis is typically caspase-dependent and non-lytic; RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis.
Can necroptosis be beneficial in cancer therapy?
Yes, ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation.
What negative regulators control necroptosis?
RUBCNL/PACER and autophagy-related proteins repress RIPK1 kinase-dependent apoptosis and necroptosis, acting as checkpoints.
How does EDITGENE support necroptosis research?
EDITGENE provides CRISPR knockout, point-mutation knock-in, knock-in, overexpression cell models, library screening, and bioinformatics services for studying GO:0060545 [3, 4, 6, 8].
Conclusion
GO:0060545 positive regulation of necroptotic process defines the molecular events that amplify a lytic, immunogenic form of cell death with broad relevance to inflammatory and oncologic disease [3, 5, 6, 8]. Core positive regulators such as RIPK1, RIPK3, MLKL, and ZBP1 are experimentally tractable, and CRISPR-based models provide causal evidence for their roles [3, 4, 6]. Understanding these mechanisms may enable therapeutic modulation of necroptosis in liver, kidney, airway, and tumor contexts [3, 5, 6, 8].
References
- 1. Andersen BM et al.. 2025. Barcoded viral tracing identifies immunosuppressive astrocyte-glioma interactions.. Nature 644(8078):1097-1106 PMID: 40562937
- 3. Zhuang Y et al.. 2024. Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses, and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1.. Hepatology 79(4):752-767 PMID: 37725754
- 4. Rojas-Rivera D et al.. 2024. The autophagy protein RUBCNL/PACER represses RIPK1 kinase-dependent apoptosis and necroptosis.. Autophagy 20(11):2444-2459 PMID: 38873940
- 5. Du J et al.. 2023. PTRF-IL33-ZBP1 signaling mediating macrophage necroptosis contributes to HDM-induced airway inflammation.. Cell Death Dis 14(7):432 PMID: 37454215
- 6. Yang Y et al.. 2021. ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation.. Sci Adv 7(41):eabf6290 PMID: 34613770
- 7. Wang B et al.. 2025. Multiple cell death modalities and immune response in pulpitis.. Int Endod J 58(1):111-127 PMID: 39257034
- 8. Wei S et al.. 2024. EIF2AK2 protein targeted activation of AIM2-mediated PANoptosis promotes sepsis-induced acute kidney injury.. Ren Fail 46(2):2403649 PMID: 39311631
